Quantum Blue® Infliximab

trough level rapid test



- Leading quantitative rapid test for infliximab monitoring
- Time to result 15 minutes
- Measuring range 0.4 to 20 µg/mL infliximab in serum, extended dilution range covering induction phase
- Standardized against the WHO NIBSC 16/170
- Validated with CE-mark for originator and biosimilars





Key features

- Quantitative rapid test for infliximab measurements
- Standardized and validated against the first WHO international standard for infliximab1 (NIBSC 16/170)
- High correlation to established third party ELISA assays
- Measuring range $0.4 20 \mu g/mL$, extendable to $180 \mu g/mL$ for induction phase
- Clinically validated^{2,3}
- Validated for Remicade®, Remsima®, Inflectra®, Zessly® and Flixabi®

Infliximab trough levels

 $<3 \mu g/mL$

Subtherapeutic level for infliximab adapt therapy4

 $3-7 \mu g/mL$

Adequate infliximab concentration⁴ $>7 \mu g/mL$

Supratherapeutic level for infliximab adapt therapy4

References

1Afonso et al., 2021, Standardization of Quantum Blue® Rapid TDM Assays with WHO International Standards for Adalimumab and Infliximab ²Parra, S. et al., 2018, Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy, Gastroenterol Res

³Magro, F. et al., 2017, Clinical performance of an infliximab rapid quantification assay, Ther Adv Gastroenterol

⁴Casteele, N. V. et al., 2015, Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease, Gastroenterology (TAXIT trial)



Ordering codes:

10 cassettes